Patents Assigned to RXi Pharmaceuticals Corporation
-
Publication number: 20190161757Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.Type: ApplicationFiled: June 28, 2018Publication date: May 30, 2019Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Publication number: 20190048341Abstract: The present disclosure relates to RNAi constructs with improved cellular uptake characteristics and methods of use of these compounds for silencing expression of long coding RNAs (IncRNAs).Type: ApplicationFiled: October 19, 2016Publication date: February 14, 2019Applicants: RXi Pharmaceuticals Corporation, Biogazelle NVInventors: James Cardia, Karen G. Bulock, Joke Hedwig Vandesompele, Gert Van Peer
-
Publication number: 20190029974Abstract: The invention pertains to the use of therapeutic approaches to treat various skin disorders and conditions. In particular, the invention pertains to the treatment of cutaneous cancers and cutaneous metastasis of solid tumors, as well as to the removal of tattoos, using a hapten. The invention provides various topical formulations comprising a hapten for treatment of these skin disorders and conditions.Type: ApplicationFiled: September 9, 2016Publication date: January 31, 2019Applicant: RXi Pharmaceuticals CorporationInventors: Gerard Cauwenbergh, Keith Johnson
-
Patent number: 10167471Abstract: The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2?-O-methyl groups at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.Type: GrantFiled: October 6, 2016Date of Patent: January 1, 2019Assignee: RXi Pharmaceuticals CorporationInventors: Joanne Kamens, Anastasia Khvorova
-
Publication number: 20180371464Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.Type: ApplicationFiled: March 12, 2018Publication date: December 27, 2018Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
-
Patent number: 10138485Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.Type: GrantFiled: September 22, 2009Date of Patent: November 27, 2018Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
-
Patent number: 10131904Abstract: The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2?-O-methyl group at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.Type: GrantFiled: February 11, 2009Date of Patent: November 20, 2018Assignee: RXi Pharmaceuticals CorporationInventors: Pamela A. Pavco, Joanne Kamens, Tod M. Woolf, William Salomon, Anastasia Khvorova
-
Publication number: 20180327748Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: ApplicationFiled: February 26, 2018Publication date: November 15, 2018Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Publication number: 20180263925Abstract: The present invention relates to methods and compositions for the treatment of alopecia areata. In some aspects, the present invention relates to haptens for use in treating alopecia areata. In other aspects, the present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds the treatment of alopecia areata. In other aspects, the present invention relates to compositions comprising haptens formulated as gels or ointments.Type: ApplicationFiled: December 3, 2015Publication date: September 20, 2018Applicant: RXi Pharmaceuticals CorporationInventors: Gerard Cauwenbergh, Keith Johnson
-
Patent number: 10041073Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.Type: GrantFiled: March 23, 2011Date of Patent: August 7, 2018Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Publication number: 20180195066Abstract: In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-?B p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.Type: ApplicationFiled: July 6, 2016Publication date: July 12, 2018Applicants: Rxi Pharmaceuticals Corporation, Synaerion TherapeuticsInventors: Michael Byrne, Antonella Favit-Vanpelt
-
Publication number: 20180195072Abstract: Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase 1 (SOD1).Type: ApplicationFiled: July 6, 2016Publication date: July 12, 2018Applicant: RXi Pharmaceuticals CorporationInventors: James Cardia, Michael Byrne, Karen G. Bulock, Pamela A. Pavco, Lyn Libertine
-
Publication number: 20180155718Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.Type: ApplicationFiled: June 30, 2017Publication date: June 7, 2018Applicant: RXi Pharmaceuticals CorporationInventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
-
Patent number: 9963702Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.Type: GrantFiled: April 14, 2016Date of Patent: May 8, 2018Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
-
Patent number: 9938530Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: GrantFiled: February 11, 2016Date of Patent: April 10, 2018Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Publication number: 20180030451Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: ApplicationFiled: September 4, 2015Publication date: February 1, 2018Applicant: RXi Pharmaceuticals CorporationInventor: Gerard Cauwenbergh
-
Patent number: 9745574Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.Type: GrantFiled: February 4, 2010Date of Patent: August 29, 2017Assignee: RXi Pharmaceuticals CorporationInventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
-
Publication number: 20170137823Abstract: The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC In addition, the antisense strand may also be modified by 2?-O-methyl groups at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.Type: ApplicationFiled: October 6, 2016Publication date: May 18, 2017Applicant: RXi Pharmaceuticals CorporationInventors: Joanne Kamens, Anastasia Khvorova
-
Publication number: 20170067056Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.Type: ApplicationFiled: April 14, 2016Publication date: March 9, 2017Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
-
Publication number: 20170051290Abstract: Aspects of the invention relate to methods for treating an ocular disorder associated with the front of the eye, comprising administering to the eye of a subject in need thereof a therapeutic RNA molecule, in an effective amount to treat an ocular disorder associated with the front of the eye.Type: ApplicationFiled: May 1, 2015Publication date: February 23, 2017Applicant: RXi Pharmaceuticals CorporationInventors: Michael Byrne, Pamela A. Pavco, Karen G. Bulock